Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828536 | 1.00 | LMNA (0.55) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3821131 | 0.91 | LMNA (0.64) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3825882 | 0.84 | LMNA (0.59) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3822798 | 0.84 | RECQL (0.56) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL5947421 | 0.82 | LMNA (0.58) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3824758 | 0.81 | RECQL (0.54) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3821668 | 0.80 | RECQL (0.52) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3823928 | 0.80 | LMNA (0.55) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3822305 | 0.80 | RECQL (0.56) | LMNARECQLSMN1; SMN2CES2CES1 | |
| SCHEMBL3826035 | 0.80 | LMNA (0.53) | LMNARECQLSMN1; SMN2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1802625-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040036-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | LIU JIN-JUN | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | CDK2, CDK1, CDK7 | LMNA 3907/4885RECQL 1534/4885SMN1; SMN2 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.